Redeye provides a research update following the Q3 report published by Isofol earlier today. The report came in largely in line with our estimates, with only a slightly lower OPEX than anticipated. With a bolstered cash position through the oversubscribed rights issue and a successfully completed second dose level in the phase Ib/II study, we continue to have a positive outlook on the company.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/